Allergy Therapeutics Share Price (AGY)

27.25 0.00 (0.00%) delayed: 5:22PM BST
Bid price 26.50 Open price 27.25
Ask price 28.00 Prev close 27.25
High price 27.44 Spread 5.36%
Low price 26.66 Volume 3,202,335

Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.

Allergy Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Allergy Therapeutics share price charts

Allergy Therapeutics Share Price Information

Name Allergy Therapeutics Epic AGY
Sector Pharmaceuticals & Biotechnology ISIN GB00B02LCQ05
Activites Allergy Therapeutics plc is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging markets. Index n/a

Allergy Therapeutics Key Numbers

Latest Share Price (p) 27.25 Net Gearing (%) 5.20
Market Capitalisation (£m) 161.71 Gross Gearing (%) 46.50
Shares in issue (m) 593.44 Debt Ratio 31.33
P/E Ratio -11.90 Debt-to-Equity Ratio 0.53
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.87
Dividend Yield (%) 0.00 Price to book value 5.33
Dividend cover (x) 0.00 ROCE (%) -27.31
Earning per share (p) -2.29 EPS Growth (%) -11,550.00
52 week high / low 30.25 / 16.38 DPS Growth (%) n/a

Allergy Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
29/09/2016 BUY Peter Jensen CH 30,000
28/09/2016 BUY Nick Wykeman FD 150,000
26/09/2016 BUY Manuel Llobet CEO 100,000
27/07/2015 BUY Manuel Llobet CEO 50,000
10/12/2012 EXR Ian Postlethwaite RES 1,500,000

More Allergy Therapeutics Director Deals >>

Allergy Therapeutics Company News

07:00 13/04/2017

Issue of Equity

RNS Number : 3752C Allergy Therapeutics PLC 13 April 2017      Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   Issue of equity in respect of the exercise of warrants and options   13 April 2017 Allergy Therapeutics (AIM:AGY), the fully...

07:15 05/04/2017

Hardman Research: Development across portfolio

RNS Number : 5821B Allergy Therapeutics PLC 05 April 2017   Hardman Research: Progressive development across portfolio Progressive development across portfolio - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro...

15:40 04/04/2017

Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLC

Numis today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 45p (from 37p). Story provided by

More Allergy Therapeutics Company News >>

Register now for FREE Allergy Therapeutics company news

Allergy Therapeutics Share Price Discussions

12 days ago

Allergy Therapeutics PLC (AGY)

Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....

11 months ago

Allergy TV Clip re: Successful Phase II Study (AGY)

more than 1 year ago

Allergy Therapeutics (AGY)

Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results.

Register now for FREE Allergy Therapeutics share price discussions